Table 3.
Anti-ADV activities of hit compounds targeting protein tyrosine kinase.
| Target | Name | CC50 (µM) | EC50 (µM) | Selective Index | ||
|---|---|---|---|---|---|---|
| AdV3 | AdV5 | AdV3 | AdV5 | |||
| EGFR 1 | AZD8931 | >5.00 | 0.05 | >5.00 | >96.15 | ND 6 |
| DesMethyl Erlotinib | >5.00 | 0.51 | >5.00 | >9.72 | ND | |
| Dacomitinib | 4.88 | 0.77 | 1.64 | 6.31 | 2.97 | |
| FGFR 2 | AZD4547 | 51.45 | 5.86 | ND | 8.78 | ND |
| PDGFR 3 | Amuvatinib | 8.34 | 3.97 | 1.80 | 2.10 | 4.64 |
| VEGFR 4 | Sorafenib Tosylate | 5.93 | 1.27 | 3.87 | 4.67 | 1.53 |
| Apatinib | >5.00 | 0.32 | 3.60 | >15.41 | >1.39 | |
| Regorafenib | 4.06 | 0.44 | 1.50 | 9.30 | 2.72 | |
| SRC 5 | KW-2449 | >5.00 | 3.66 | 1.28 | >1.37 | >3.91 |
| SYK 6 | R406 | >5.00 | 0.94 | >5.00 | >5.32 | ND |
| R788 | 1.56 | 0.23 | 1.06 | 6.65 | 1.48 | |
1 EGFR: Epidermal growth factor receptor; 2 FGFR: Fibroblast growth factor receptor. 3 PDGFR: Platelet-derived growth factor receptor; 4 SRC: Short for sarcoma, a non-receptor tyrosine kinase. 5 SYK: Spleen tyrosine kinase, a non-receptor tyrosine kinase. 6 ND: Not determined.